Joo Han Lim
Overview
Explore the profile of Joo Han Lim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
426
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim J, Cho J, Lim J, Lee M
Blood Res
. 2025 Jan;
60(1):1.
PMID: 39747710
Purpose: This network meta-analysis aimed to evaluate the relative efficacy of systemic treatments in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), focusing on key genetic mutations, specifically the 17p...
2.
Lee D, Lee C, Kim H, Sym S, Zang D, Kim K, et al.
Cancer Res Treat
. 2024 Nov;
PMID: 39529388
Purpose: The nProfiler 1 Stomach Cancer Assay (nProfiler1), designed to predict responses to fluorouracil-based adjuvant chemotherapy, measures the expression of four gastric cancer target genes (GZMB, WARS, SFRP4, and CDX1)....
3.
Lee J, Lee P, Yoon Y, Han B, Ko S, Park M, et al.
Biomed Pharmacother
. 2023 Apr;
162:114716.
PMID: 37086509
Pancreatic ductal adenocarcinoma (PDAC) exhibits a pronounced extracellular matrix (ECM)-rich response, which is produced by an excessive amount of transforming growth factor β (TGF-β), resulting in tumor progression and metastasis....
4.
Ko S, Jung K, Yoon Y, Han B, Park M, Lee Y, et al.
Am J Cancer Res
. 2022 Oct;
12(9):4326-4342.
PMID: 36225647
Pancreatic ductal adenocarcinoma (PDAC) is an extracellular matrix (ECM)-rich carcinoma, which promotes chemoresistance by inhibiting drug diffusion into the tumor. Discoidin domain receptor 1 (DDR1) increases tumor progression and drug...
5.
Han B, Jung K, Lee J, Yoon Y, Ko S, Park M, et al.
Am J Cancer Res
. 2022 Aug;
12(7):3083-3098.
PMID: 35968350
The use of anesthetics in the surgical resection of tumors may influence the prognosis of cancer patients. Lidocaine, a local anesthetic, is known to act as a chemosensitizer and relieve...
6.
Ha H, Lim J
Brain Tumor Res Treat
. 2022 Aug;
10(3):158-163.
PMID: 35929113
Cytotoxic chemotherapy has been a mainstay of cancer treatment since the 1940s. In the recent era of emergent targeted therapies and immunotherapies, many cytotoxic chemotherapy agents including temozolomide are still...
7.
Ha H, Jeong Y, Lim J, Suh Y
Int J Environ Res Public Health
. 2022 Feb;
19(4).
PMID: 35206499
Although approximately 50% of patients with acute myeloid leukemia (AML) are diagnosed over the age of 60 years, there is currently no established consensus on the treatment of elderly AML...
8.
Kim J, Ha H, Park J, Cho J, Lim J, Lee M
J Cancer
. 2022 Jan;
13(2):364-372.
PMID: 35069886
Although smoking status has potential as a biomarker for immune checkpoint blockade in advanced non-small cell lung cancer (NSCLC), its clinical significance remains obscure. This meta-analysis aims to assess the...
9.
Nam H, Hong S, Jung K, Kang S, Park M, Kang S, et al.
J Natl Cancer Inst
. 2021 Oct;
114(2):228-234.
PMID: 34613397
Background: Pancreatic cancer (PC) has a grim prognosis, and an early diagnostic biomarker has been highly desired. The molecular link between diabetes and PC has not been well established. Methods:...
10.
Lee J, Kang Y, Jung K, Son M, Shin S, Kim J, et al.
Cancer Lett
. 2021 Mar;
507:97-111.
PMID: 33744388
KRAS mutation is associated with the progression and growth of pancreatic cancer and contributes to chemo-resistance, which poses a significant clinical challenge in pancreatic cancer. Here, we developed a RT22-ep59...